Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Novel TGF-β inhibitors ready for prime time in onco-immunology.

de Gramont A, Faivre S, Raymond E.

Oncoimmunology. 2016 Dec 7;6(1):e1257453. doi: 10.1080/2162402X.2016.1257453. eCollection 2017. Review.

2.

Targeted Therapy in Systemic Sclerosis.

Baron M.

Rambam Maimonides Med J. 2016 Oct 31;7(4). doi: 10.5041/RMMJ.10257. Review.

3.

Recent Advances in Treatments of Primary Focal Segmental Glomerulosclerosis in Children.

Han KH, Kim SH.

Biomed Res Int. 2016;2016:3053706. doi: 10.1155/2016/3053706. Epub 2016 Apr 18. Review.

4.

Focal segmental glomerulosclerosis: molecular genetics and targeted therapies.

Chen YM, Liapis H.

BMC Nephrol. 2015 Jul 9;16:101. doi: 10.1186/s12882-015-0090-9. Review.

5.

Treatment of idiopathic focal segmental glomerulosclerosis: options in the event of resistance to corticosteroids and calcineurin inhibitors.

Segarra-Medrano A, Jatem-Escalante E, Agraz-Pamplona I, Carnicer-Cáceres C, Ramos-Terrades N, Ostos-Roldán E, Quiles-Pérez MT, Arbós-Via MA.

Nefrologia. 2013;33(4):448-61. doi: 10.3265/Nefrologia.pre2013.Jan.11871. Review. English, Spanish.

Supplemental Content

Loading ...
Support Center